Trial · NCT02098746
Results by group21
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 21
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Frequency of Adverse Drug Reactions | Pioglitazone/Glimepiride | Anaemia | 1 | participants | |
| Frequency of Adverse Drug Reactions | Pioglitazone/Glimepiride | Hypoglycaemia | 7 | participants | |
| Frequency of Adverse Drug Reactions | Pioglitazone/Glimepiride | Generalised oedema | 1 | participants | |
| Frequency of Adverse Drug Reactions | Pioglitazone/Glimepiride | Oedema | 1 | participants | |
| Frequency of Adverse Drug Reactions | Pioglitazone/Glimepiride | Weight increased | 6 | participants | |
| Change From Baseline in Glycosylated Hemoglobin (HbA1c) | Pioglitazone/Glimepiride | Month 3 (n=234) | -0.83 | Standard Deviation 1.030 | percent |
| Change From Baseline in Glycosylated Hemoglobin (HbA1c) | Pioglitazone/Glimepiride | Month 6 (n=190) | -0.84 | Standard Deviation 1.094 | percent |
| Change From Baseline in Glycosylated Hemoglobin (HbA1c) | Pioglitazone/Glimepiride | Month 9 (n=177) | -0.83 | Standard Deviation 1.088 | percent |
| Change From Baseline in Glycosylated Hemoglobin (HbA1c) | Pioglitazone/Glimepiride | Month 12 (n=84) | -0.62 | Standard Deviation 1.139 | percent |
| Change From Baseline in Glycosylated Hemoglobin (HbA1c) | Pioglitazone/Glimepiride | Final Assessment (n=247) | -0.92 | Standard Deviation 1.285 | percent |
| Change From Baseline in Fasting Blood Glucose Level | Pioglitazone/Glimepiride | Month 3 (n=76) | -15.9 | Standard Deviation 35.99 | mg/dL |
| Change From Baseline in Fasting Blood Glucose Level | Pioglitazone/Glimepiride | Month 6 (n=59) | -23.2 | Standard Deviation 40.11 | mg/dL |
| Change From Baseline in Fasting Blood Glucose Level | Pioglitazone/Glimepiride | Month 9 (n=53) | -12.7 | Standard Deviation 37.60 | mg/dL |
| Change From Baseline in Fasting Blood Glucose Level | Pioglitazone/Glimepiride | Month 12 (n=28) | -17.0 | Standard Deviation 20.42 | mg/dL |
| Change From Baseline in Fasting Blood Glucose Level | Pioglitazone/Glimepiride | Final Assessment (n=83) | -17.7 | Standard Deviation 42.23 | mg/dL |
| Change From Baseline in Fasting Insulin Level | Pioglitazone/Glimepiride | Month 3 (n=33) | 1.66 | Standard Deviation 9.419 | μU/dL |
| Change From Baseline in Fasting Insulin Level | Pioglitazone/Glimepiride | Month 6 (n=25) | -0.25 | Standard Deviation 3.976 | μU/dL |
| Change From Baseline in Fasting Insulin Level | Pioglitazone/Glimepiride | Month 9 (n=17) | 1.32 | Standard Deviation 3.949 | μU/dL |
| Change From Baseline in Fasting Insulin Level | Pioglitazone/Glimepiride | Month 12 (n=15) | -0.29 | Standard Deviation 3.489 | μU/dL |
| Change From Baseline in Fasting Insulin Level | Pioglitazone/Glimepiride | Final Assessment (n=39) | 0.98 | Standard Deviation 7.310 | μU/dL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02098746/results